{"id":25861,"date":"2025-02-07T23:01:25","date_gmt":"2025-02-07T15:01:25","guid":{"rendered":"https:\/\/flcube.com\/?p=25861"},"modified":"2025-02-07T23:01:27","modified_gmt":"2025-02-07T15:01:27","slug":"innovent-biologics-posts-strong-q4-sales-eyes-2025-product-launches","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25861","title":{"rendered":"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches"},"content":{"rendered":"\n

China-based Innovent Biologics Inc. (HKG: 1801<\/a>) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market uptake of the company’s PD-1 inhibitor Tyvyt (sintilimab injection), as well as increased sales of other products.<\/p>\n\n\n\n

Upcoming Product Launches<\/strong>
Innovent is poised for further growth with the expected market launch of three anti-tumor drugs in 2025. Among the six innovative products set for launch, Daboyue (taletrectinib) is an ROS1 tyrosine kinase inhibitor targeting lung cancer. The company also plans to launch EGFR inhibitor Aoyixin (limertinib) and Jaypirca (pirtobrutinib), a BTK inhibitor for blood cancer. These launches are expected to bolster Innovent’s position in the oncology market.<\/p>\n\n\n\n

Future Outlook<\/strong>
With strong Q4 sales and a robust pipeline of innovative products, Innovent Biologics is well-positioned for continued growth in 2025. The upcoming launches highlight the company’s commitment to advancing treatments for various cancers, further solidifying its presence in the global biopharmaceutical market.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD…<\/p>\n","protected":false},"author":1,"featured_media":25862,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[910,198],"class_list":["post-25861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-hkg-1801","tag-innovent-biologics"],"yoast_head":"\nInnovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market uptake of the company's PD-1 inhibitor Tyvyt (sintilimab injection), as well as increased sales of other products.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25861\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches\" \/>\n<meta property=\"og:description\" content=\"China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market uptake of the company's PD-1 inhibitor Tyvyt (sintilimab injection), as well as increased sales of other products.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25861\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-07T15:01:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-07T15:01:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0722-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches\",\"datePublished\":\"2025-02-07T15:01:25+00:00\",\"dateModified\":\"2025-02-07T15:01:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861\"},\"wordCount\":187,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0722-png.avif\",\"keywords\":[\"HKG: 1801\",\"Innovent Biologics\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25861#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25861\",\"name\":\"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0722-png.avif\",\"datePublished\":\"2025-02-07T15:01:25+00:00\",\"dateModified\":\"2025-02-07T15:01:27+00:00\",\"description\":\"China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market uptake of the company's PD-1 inhibitor Tyvyt (sintilimab injection), as well as increased sales of other products.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25861\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0722-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/0722-png.avif\",\"width\":1080,\"height\":607,\"caption\":\"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25861#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches - Insight, China's Pharmaceutical Industry","description":"China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market uptake of the company's PD-1 inhibitor Tyvyt (sintilimab injection), as well as increased sales of other products.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25861","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches","og_description":"China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market uptake of the company's PD-1 inhibitor Tyvyt (sintilimab injection), as well as increased sales of other products.","og_url":"https:\/\/flcube.com\/?p=25861","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-02-07T15:01:25+00:00","article_modified_time":"2025-02-07T15:01:27+00:00","og_image":[{"width":1080,"height":607,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0722-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25861#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25861"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches","datePublished":"2025-02-07T15:01:25+00:00","dateModified":"2025-02-07T15:01:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25861"},"wordCount":187,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=25861#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0722-png.avif","keywords":["HKG: 1801","Innovent Biologics"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25861#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25861","url":"https:\/\/flcube.com\/?p=25861","name":"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=25861#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=25861#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0722-png.avif","datePublished":"2025-02-07T15:01:25+00:00","dateModified":"2025-02-07T15:01:27+00:00","description":"China-based Innovent Biologics Inc. (HKG: 1801) reported product sales of over RMB 2 billion (USD 274 million) in Q4 2024, up 25% year-on-year (YOY). For the full year, sales reached RMB 8.2 billion (USD 1.1 billion), marking a 40% increase YOY. The strong performance was driven by continued robust market uptake of the company's PD-1 inhibitor Tyvyt (sintilimab injection), as well as increased sales of other products.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25861#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25861"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=25861#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0722-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0722-png.avif","width":1080,"height":607,"caption":"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25861#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics Posts Strong Q4 Sales, Eyes 2025 Product Launches"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/02\/0722-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25861"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25861\/revisions"}],"predecessor-version":[{"id":25863,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25861\/revisions\/25863"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/25862"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}